Retrospective case note review of chronic spontaneous urticaria outcomes and adverse effects in patients treated with omalizumab or ciclosporin in UK secondary care

[1]  Michihiro Hide,et al.  The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update , 2015 .

[2]  S. Spector,et al.  Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study. , 2015, The Journal of investigative dermatology.

[3]  A. Gnanasakthy,et al.  Changes in urticaria symptoms, dermatologic-related quality of life, and urticaria-specific quality of life: are they telling us the same thing about response to treatment for chronic spontaneous/idiopathic urticaria (CSU/CIU)? , 2014 .

[4]  M. Maurer,et al.  Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. , 2014, Journal of dermatological science.

[5]  J. Silvestre,et al.  Omalizumab in the treatment of chronic urticaria. , 2014, Actas dermo-sifiliograficas.

[6]  J. Bartra,et al.  Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice , 2013, Expert opinion on biological therapy.

[7]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[8]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[9]  T. Zuberbier,et al.  Management of chronic spontaneous urticaria in real life – in accordance with the guidelines? A cross‐sectional physician‐based survey study , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[10]  T. Zuberbier,et al.  Diagnosis and Treatment of Urticaria and Angioedema: A Worldwide Perspective , 2012, The World Allergy Organization journal.

[11]  D. Khan,et al.  Calcineurin inhibitors in chronic urticaria , 2012, Current opinion in allergy and clinical immunology.

[12]  J. Bousquet,et al.  Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report 1 , 2011, Allergy.

[13]  A. Kessel,et al.  Cyclosporine‐A in severe chronic urticaria: the option for long‐term therapy , 2010, Allergy.

[14]  S. Büyüköztürk,et al.  Psychiatric morbidity and quality of life in patients with chronic idiopathic urticaria. , 2007, Annals of Allergy, Asthma & Immunology.

[15]  G. Vena,et al.  Cyclosporine in chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. , 2006, Journal of the American Academy of Dermatology.

[16]  M. T. Caballero,et al.  Epidemiology of urticaria in Spain. , 2004, Journal of investigational allergology & clinical immunology.

[17]  P. Pasquini,et al.  Psychiatric morbidity in dermatological outpatients: an issue to be recognized , 2000, The British journal of dermatology.

[18]  P. Seed,et al.  Randomized double‐blind study of cyclosporin in chronic ‘idiopathic’ urticaria , 2000, The British journal of dermatology.

[19]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.